Ask AI
ProCE Banner Activity

PARP Combinations in Prostate Cancer: PARPi Plus Androgen Receptor Inhibitors

Slideset Download
Download these slides from a live Webinar to gain expert insight on the rationale for combining PARP inhibitors and AR-directed therapy in mCRPC including the latest evidence from ASCO GU 2021.

Released: February 19, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer TEXT Only

Faculty Disclosure

Primary Author

Neal D. Shore, MD, FACS

Head of GU Oncology Center of Excellence
The START Center for Cancer Research
Medical Director
START Carolinas
The START Center for Cancer Research
Myrtle Beach, South Carolina